About the Institute
Located on the main campus of Utah State University, the Institute for Antiviral Research (IAR) comprises a team of recognized scientists working to identify antiviral agents and vaccines against a wide range of human pathogenic viruses. Five principal investigators and research staff work collaboratively at the IAR, with shared expertise in respiratory, hemorrhagic fever, and neuroinvasive viruses.
Since being founded in 1978, the IAR and its researchers have been involved in the pre-clinical development of several FDA-approved antiviral compounds, including ribavirin (Virazole™), ganciclovir (Cytovene™), stavudine (Zerit™), and oseltamivir (Tamiflu™), as well as T-705 (Avigan®) which is approved for clinical use in Japan and being evaluated in the U.S. Researchers at the IAR completed studies evaluating the in vitro and in vivo efficacy to support FDA approval.
In addition to receiving funding from the National Institutes of Health and the Department of Defense, the IAR also performs fee-for-service testing for the private sector, academic groups, and research institutes nationally and internationally. The IAR has established and developed numerous in vitro and in vivo viral infection and disease models over the past 45 years.